Investigation of the curative effect of chemotherapy combined with DC-CIK cell immunotherapy in metastatic breast carcinoma

doi:10.3760/cma.j.issn.1673-422X.2016.05.002

Abstract

Abstract: ObjectiveTo compare the efficacy and adverse reactions of TA regimen (docetaxel + epirubicin) and immunization therapy of TA regimen combined with dendritic cell (DC)cytokine induced killer cell (CIK) in treating the patients with metastatic breast cancer (MBC). MethodsClinical data of 43 patients with MBC received treatment in our hospital from January 2011 to January 2013 were retrospectively analyzed. Patients included were divided into two groups according to the treatment, simple treatment group (TA regimen, control group, 22 cases) and combined treatment group (TA regimen + DCCIK cell, observation group, 21 cases). The curative effect, improvement situation of clinical symptoms, adverse reactions and changes of T cell immune phenotype in peripheral blood of patients before and after treatment in the two groups were compared. ResultsThe total efficiency of treatment in observation group (85.7%) was higher than that in control group (63.6%), and the difference was statistical significant (χ2=4.949, P=0.026). Among the incidences of all kinds of adverse reaction appeared during the treatment in two groups, the white blood cells count decreased was the highest in observation group (76.2%) and in control group (59.1%), the difference had no statistical significance (χ2=0.858, P=0.36). After treatment, the rates of fatigue, loss of appetite, insomnia and night sweats of patients in observation group were lower than those in control group (23.8% vs. 54.5%, χ2=4.246, P=0.04; 19.0% vs. 54.5%, χ2=5.795, P=0.02; 19.0% vs. 50.0%, χ2=4.532, P=0.03). The CD3+ (60.4±12.3 vs. 47.4±12.8, t=3.393, P<0.01), CD3+/CD4+ (41.7±9.6 vs. 28.1±10.5, t=5.442, P<0.01), CD4+/CD8+ (1.5±0.2 vs. 1.0±0.2, t=8.195, P<0.01), NK cells (27.3±5.9 vs. 15.3±6.1, t=6.643, P<0.01), NK T cells (14.7±1.4 vs. 6.0±1.2, t=11.020, P<0.01) after treatment in observation group were obviously higher than those in control group. ConclusionComparing with the pure TA scheme, the curative effect of immunization therapy of TA regimen combined with DCCIK cell in treating the patients with MBC is better. It significantly improves the immune functions of patients with MBC, and does not increase adverse reaction.

Key words: Breast neoplasms, Immunotherapy, Antineoplastic combined chemotherapy protocols

Gao Haiyan, Zhu Yulan, Sun Li. Investigation of the curative effect of chemotherapy combined with DC-CIK cell immunotherapy in metastatic breast carcinoma[J]. Journal of International Oncology, 2016, 43(5): 326-329.

References

［1］ Martin TA, Jiang WG. Evaluation of the expression of stem cell markers in human breast cancer reveals a correlation with clinical progression and metastatic disease in ductal carcinoma［J］. Oncol Rep, 2014, 31(1): 262-272. DOI: 10.3892/or.2013.2813. ［2］ Xiao C, Gong Y, Han EY, et al. Stability of HER2positive status in breast carcinoma: a comparison between primary and paired metastatic tumors with regard to the possible impact of intervening trastuzumab treatment［J］. Ann Oncol, 2011, 22(7): 1547-1553. DOI: 10.1093/annonc/mdq623. ［3］ Noda S, Kashiwagi S, Kawajiri H, et al. A case of metastatic breast carcinoma of the cervical muscles［J］. Gan To Kagaku Ryoho, 2013, 40(12): 2405-2407. ［4］ Liu YY, Patwardhan GA, Xie P, et al. Glucosylceramide synthase, a factor in modulating drug resistance, is overexpressed in metastatic breast carcinoma［J］. Int J Oncol, 2011, 39(2): 425-431. DOI: 10.3892/ijo.2011.1052. ［5］ Taylor SK, Chia S, Dent S, et al. A phase Ⅱ study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: a trial of the Princess Margaret Hospital phase Ⅱ consortium［J］. Oncologist, 2010, 15(8): 810-818. DOI: 10.1634/theoncologist.20100081. ［6］ Gong Y, Han EY, Guo M, et al. Stability of estrogen receptor status in breast carcinoma: a comparison between primary and metastatic tumors with regard to disease course and intervening systemic therapy［J］. Cancer, 2011, 117(4): 705-713. DOI: 10.1002/cncr.25506. ［7］ Ozdemir N, Aksoy S, Sendur MA, et al. Capecitabine/cisplatin doublet in anthracycline and taxane pretreated and HER2 negative metastatic breast carcinoma patients［J］. J BUON, 2013, 18(4): 831-837. ［8］ Wong MH, Yiu MK, Ho KL. Metastatic carcinoma of breast in the urinary bladder［J］. Hong Kong Med J, 2013, 19(5): 455-457.

[1]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[2]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[3]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[4]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[5]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua. Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy [J]. Journal of International Oncology, 2024, 51(5): 257-266.
[6]	Yang Hao, Shi Guidong, Zhang Chengcheng, Zhang Yue, Zhang Liwen, Fu Maoyong. Comparison of efficacy and safety between sintilimab and tislelizumab in neoadjuvant therapy for advanced esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2024, 51(4): 210-216.
[7]	Sa Qiang, Xu Hangcheng, Wang Jiayu. Advances in immunotherapy for breast cancer [J]. Journal of International Oncology, 2024, 51(4): 227-234.
[8]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong. Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer [J]. Journal of International Oncology, 2024, 51(4): 235-238.
[9]	Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao. Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes [J]. Journal of International Oncology, 2024, 51(3): 143-150.
[10]	Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan. Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 175-180.
[11]	Chen Boguang, Wang Sugui, Zhang Yongjie. Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer [J]. Journal of International Oncology, 2024, 51(2): 73-82.
[12]	Jiang Xi, Wu Yongcun, Liang Yan, Chu Li, Duan Yingxin, Wang Lijun, Huo Junjie. Impact of pembrolizumab combined with chemotherapy on angiogenesis and circulating endothelial cells in patients with advanced non-small cell lung cancer [J]. Journal of International Oncology, 2024, 51(2): 89-94.
[13]	Gu Huayan, Zhu Teng, Guo Guilong. Breast microbiota and breast cancer： present and future [J]. Journal of International Oncology, 2024, 51(1): 55-58.
[14]	Wang Jing, Xu Wenting. Value of NLR， CEA combined with coagulation indicators in the differential diagnosis of benign and malignant breast nodules with a diameter ≤ 1.0 cm [J]. Journal of International Oncology, 2023, 50(9): 520-526.
[15]	Feng Chengtian, Huang Furong, Cao Shiyu, Wang Jianyu, Nanding Abiyasi, Jiang Yongdong, Zhu Juanying. Relationships between HER2 protein expression and imaging features in HER2 positive breast cancer patients [J]. Journal of International Oncology, 2023, 50(9): 527-531.